Evaluation of kidney dysfunction in childhood cancer survivors.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
27
3
2022
medline:
24
12
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
The major increase in the survival rate among children with cancer is due to improvement in the diagnosis and treatment. Despite this increase, childhood cancer survivors (CCS) are at high risk of developing late complications such as nephrotoxicity due to chemotherapy. So, we aimed to detect early subclinical kidney dysfunction among CCS. This cross-sectional study was implemented on 52 survivors of childhood cancer recruited from Pediatric Oncology Unit, Menoufia University. Laboratory evaluations for each participant, including complete blood count, serum urea, creatinine, urinary protein, urinary calcium, uric acid, and serum cystatin C and urinary Neutrophil Gelatinase Associated Lipocalin (UrNGAL) by ELISA were obtained. Estimated GFR was decreased in 23.1% of cases, with elevated serum cystatin C, UrNGAL and UrNGAL/Cr. There was a significant increase of Uprotein/Cr, UCa/Cr, UACR (p = 0.02), UrNGAL and UrNGAL/Cr (P < 0.001) in patients with tubular dysfunction compared without tubular dysfunction. There was a significant difference between two groups regarding cisplatin (P = 0.03) and high-dose methotrexate chemotherapy (p = 0.04). The AUCs for detecting kidney tubular dysfunction by UrNGAL and UrNGAL/Cr were 0.807 and 0.747. A significant tubular dysfunction among childhood cancer survivors receiving chemotherapy as cisplatin and high-dose methotrexate. Detection of kidney dysfunction mainly tubular in childhood cancer survivors after finishing chemotherapy. Urinary NGAL is a good predictor for detection of tubular dysfunction in childhood cancer survivors after finishing chemotherapy.
Sections du résumé
BACKGROUND
The major increase in the survival rate among children with cancer is due to improvement in the diagnosis and treatment. Despite this increase, childhood cancer survivors (CCS) are at high risk of developing late complications such as nephrotoxicity due to chemotherapy. So, we aimed to detect early subclinical kidney dysfunction among CCS.
METHODS
This cross-sectional study was implemented on 52 survivors of childhood cancer recruited from Pediatric Oncology Unit, Menoufia University. Laboratory evaluations for each participant, including complete blood count, serum urea, creatinine, urinary protein, urinary calcium, uric acid, and serum cystatin C and urinary Neutrophil Gelatinase Associated Lipocalin (UrNGAL) by ELISA were obtained.
RESULTS
Estimated GFR was decreased in 23.1% of cases, with elevated serum cystatin C, UrNGAL and UrNGAL/Cr. There was a significant increase of Uprotein/Cr, UCa/Cr, UACR (p = 0.02), UrNGAL and UrNGAL/Cr (P < 0.001) in patients with tubular dysfunction compared without tubular dysfunction. There was a significant difference between two groups regarding cisplatin (P = 0.03) and high-dose methotrexate chemotherapy (p = 0.04). The AUCs for detecting kidney tubular dysfunction by UrNGAL and UrNGAL/Cr were 0.807 and 0.747.
CONCLUSION
A significant tubular dysfunction among childhood cancer survivors receiving chemotherapy as cisplatin and high-dose methotrexate.
IMPACT
Detection of kidney dysfunction mainly tubular in childhood cancer survivors after finishing chemotherapy. Urinary NGAL is a good predictor for detection of tubular dysfunction in childhood cancer survivors after finishing chemotherapy.
Identifiants
pubmed: 35338352
doi: 10.1038/s41390-022-02015-w
pii: 10.1038/s41390-022-02015-w
pmc: PMC9771802
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Cystatin C
0
Methotrexate
YL5FZ2Y5U1
Lipocalin-2
0
Biomarkers
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1689-1694Informations de copyright
© 2022. The Author(s).
Références
Geenen, M. M. et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA-J. AM MED ASSOC 297, 2705–2715 (2007).
doi: 10.1001/jama.297.24.2705
Gatta, G. et al. Survival of European children and young, adults with cancer diagnosed 1995–2002. Eur. J. Cancer 45, 992–1005 (2009). https://doi.org/10.1016/j.ejca.2008.11.042 .
doi: 10.1016/j.ejca.2008.11.042
Ruggiero, A., Ferrara, P., Attinà, G., Rizzo, D. & Riccardi, R. Renal toxicity and chemotherapy in children with cancer. Br. J. Clin. Pharmacol. 83, 2605–2614 (2017). https://doi.org/10.1111/bcp.13388 .
doi: 10.1111/bcp.13388
Lankelma, J. & van der Klein, E. The role of 7-hydroxymethotrexate during methotrexate anticancer chemotherapy. Cancer Lett. 9, 133–142 (1980). https://doi.org/10.1016/0304-3835(80)90117-2 .
doi: 10.1016/0304-3835(80)90117-2
Tanaka, A., Suemaru, K. & Araki, H. A new approach for evaluating renal function and its practical application. J. Pharmacol. Sci. 105, 1–5 (2007). https://doi.org/10.1254/jphs.cp0070058 .
doi: 10.1254/jphs.cp0070058
Mishra, J. et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24, 307–315 (2004). https://doi.org/10.1159/000078452 .
doi: 10.1159/000078452
Schwartz, G. J. et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 20, 629–637 (2009). https://doi.org/10.1681/ASN.2008030287 .
doi: 10.1681/ASN.2008030287
Knijnenburg, S. L. et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst. Rev. CD008944. (2013). https://doi.org/10.1002/14651858.CD008944.pub2
Blufpand, H. N., Hes, N., Bökenkamp, A., van de Wetering, M. D. & Kaspers, G. J. Diversity in renal function monitoring and dose modifications during treatment for childhood cancer: a call for standardization. Pediatr. Blood Cancer 61, 337–344 (2014). https://doi.org/10.1002/pbc.24572 .
doi: 10.1002/pbc.24572
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39, S1–266 (2002).
Erdem, A. Y., Emir, S., Çakar, N., Demir, H. A. & Özyörük, D. Examination of nephrotoxicity in survivors of childhood cancer and comparison of methods for estimating glomerular filtration rate. İzmir Dr. Behçet. Uz Çocuk Hast. Derg. 11, 139–146 (2021). https://doi.org/10.5222/buchd.2021.90377 .
doi: 10.5222/buchd.2021.90377
Dekkers, I. A. et al. Long-term nephrotoxicity in adult survivors of childhood cancer. Clin. J. Am. Soc. Nephrol. 8, 922–929 (2013). https://doi.org/10.2215/CJN.09980912 .
doi: 10.2215/CJN.09980912
Kooijmans, E. C. et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst. Rev. 3, CD008944 (2019). https://doi.org/10.1002/14651858.CD008944.pub3 .
doi: 10.1002/14651858.CD008944.pub3
Barnett, L. M. A. & Cummings, B. S. Nephrotoxicity and renal pathophysiology: a contemporary perspective. Toxicol. Sci. 164, 379–390 (2018). https://doi.org/10.1093/toxsci/kfy159 .
doi: 10.1093/toxsci/kfy159
Widemann, B. C. et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100, 2222–2232 (2004). https://doi.org/10.1002/cncr.20255 .
doi: 10.1002/cncr.20255
Oberlin, O. et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J. Clin. Oncol. 27, 5350–5355 (2009). https://doi.org/10.1200/JCO.2008.17.5257 .
doi: 10.1200/JCO.2008.17.5257
Knijnenburg, S. L. et al. Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin. J. Am. Soc. Nephrol. 7, 1416–1427 (2012). https://doi.org/10.2215/CJN.09620911 .
doi: 10.2215/CJN.09620911
Mehdiabadi, G. B. Otukesh, H., Shamsabadi, R. H., Arjomand M. E. Long-term follow-up of renal disorders in children with ALL by evaluating urine NGAL. J. Ped. Nephrol. 7, (2019). https://doi.org/10.22037/jpn.v7i2.24506 .
Sterling, M. et al. Urine biomarkers of acute kidney injury in noncritical ill, hospitalized children treated with chemotherapy. Pediatr. Blood Cancer. 64, (2017). https://doi.org/10.1002/pbc.26538 .
Latoch, E. et al. Urine NGAL and KIM-1—tubular injury biomarkers in long-term survivors of childhood solid tumors: A Cross-Sectional Study. J. Clin. Med. 10, 399 (2021). https://doi.org/10.3390/jcm10030399 .
doi: 10.3390/jcm10030399
Li, H., Xu, Q., Wang, Y., Chen, K. & Li, J. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia. Cancer Chemother., Pharm. 85, 95–103 (2020). https://doi.org/10.1007/s00280-019-03980-6 .
doi: 10.1007/s00280-019-03980-6
Barnfield, M. C. et al. Cystatin C in assessment of glomerular filtration rate in children and young adults suffering from cancer. Nucl. Med. Commun. 34, 609–614 (2013). https://doi.org/10.1097/MNM.0b013e328360d929 .
doi: 10.1097/MNM.0b013e328360d929
Lankisch, P. et al. Serum cystatin C is a suitable marker for routine monitoring of renal function in pediatric cancer patients, especially of very young age. Pediatr. Blood Cancer 46, 767–772 (2006). https://doi.org/10.1002/pbc.20581 .
doi: 10.1002/pbc.20581